HBK INVESTMENTS L P - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 16 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
HBK INVESTMENTS L P ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q2 2022$44,830,000
+17.5%
48,455,000
+21.3%
0.25%
+58.8%
Q1 2022$38,147,000
+15.5%
39,945,000
+16.8%
0.16%
+30.1%
Q4 2021$33,023,000
+58.5%
34,195,000
+52.0%
0.12%
+50.0%
Q3 2021$20,832,00022,500,0000.08%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q2 2022
NameSharesValueWeighting ↓
LINDEN ADVISORS LP 71,957,000$88,374,0003.14%
Context Capital Management, LLC 3,500,000$4,288,0002.87%
Mohican Financial Management, LLC 1,000,000$1,250,0002.40%
Verition Fund Management LLC 8,000,000$9,835,0000.79%
ZAZOVE ASSOCIATES LLC 8,170,000$10,024,0000.51%
Baupost Group 30,000,000$37,125,0000.46%
WOLVERINE ASSET MANAGEMENT LLC 24,020,000$29,431,0000.33%
SSI INVESTMENT MANAGEMENT LLC 3,007,000$3,683,0000.31%
CSS LLC/IL 2,900,000$3,556,0000.17%
Rock Springs Capital Management LP 1,500,000$1,844,0000.08%
View complete list of THERAVANCE BIOPHARMA INC shareholders